An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy.

Superficial bladder cancer accounts for approximately 70% to 80% of all newly diagnosed bladder cancers. The vast majority of these cancers are transitional bladder tumors of various histologic grades (I to III). Superficial tumors include carcinoma in situ (CIS), tumors confined to the epithelium (Ta), and superficial tumors that invade the lamina propria (T1) but do not involve superficial muscle layers. The primary treatment for eradication of stage Ta and T1 bladder cancers is transurethral resection of the tumor. Many patients with superficial bladder tumors treated with endoscopic surgery alone have recurrence or tumor progression at some point in their follow-up, and, in these patients, the need for adjuvant treatment becomes a major concern.

[1]  I. Fukui,et al.  Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result. , 1994, The Journal of urology.

[2]  O. Dalesio,et al.  Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone. , 1982, European urology.

[3]  H. T. Herring THE TREATMENT OF VESICAL PAPILLOMA BY INJECTIONS , 1903, British medical journal.

[4]  Richard Sylvester,et al.  Long-Term Follow-Up of an EORTC Randomized Prospective Trial Comparing Intravesical Bacille Calmette-Guerin-RIVM and Mitomycin C in Superficial Bladder Cancer , 1999 .

[5]  Thomas D. Schmittgen,et al.  Correlation of human bladder tumor histoculture proliferation and sensitivity to mitomycin C with tumor pathobiology. , 1994, The Journal of urology.

[6]  P. Nieh,et al.  A longitudinal study of patients with superficial bladder carcinoma successfully treated with weekly intravesical thio-tepa. , 1979, The Journal of urology.

[7]  W. Frable,et al.  The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder. , 1981, The Journal of urology.

[8]  M. Soloway,et al.  Thiotepa-induced myelosuppression: review of 670 bladder instillations. , 1983, The Journal of urology.

[9]  M. Parmar,et al.  The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. , 1996, The Journal of urology.

[10]  B. Ali-El-Dein,et al.  Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. , 1997, The Journal of urology.

[11]  R. Bahnson,et al.  Initial report on intraves1cal administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder , 1997 .

[12]  U. Nseyo,et al.  Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. , 1995, The Journal of urology.

[13]  W. Lutzeyer,et al.  Natural history and treatment of low and high risk superficial bladder tumors. , 1988, The Journal of urology.

[14]  Sarosdy Mf Principles of intravesical chemotherapy and immunotherapy. , 1992 .

[15]  E. Solsona,et al.  Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. , 1999, The Journal of urology.

[16]  K. Burnand,et al.  Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. , 1976, British journal of urology.

[17]  F. Schröder,et al.  Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. , 1997, The Journal of urology.

[18]  S. Naito,et al.  Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone , 1998, Cancer Chemotherapy and Pharmacology.

[19]  S. Loening,et al.  Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. , 1983, The Journal of urology.

[20]  P. Whelan,et al.  Intravesical mitozantrone in recurrent superficial bladder cancer: a phase II study. , 1995, British journal of urology.

[21]  M. Parmar,et al.  Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party) , 1988, British medical journal.

[22]  C. Lee,et al.  Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor. , 1989, The Journal of urology.

[23]  K. Jauhiainen,et al.  Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group. , 1996, The Journal of urology.

[24]  K. Kurth,et al.  Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder. , 1991, The Journal of urology.

[25]  K. Jauhiainen,et al.  Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. , 1995, The Journal of urology.

[26]  H. Huland,et al.  Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy? , 1997, European Urology.

[27]  Luc Bijnens,et al.  A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer , 1996 .

[28]  J. Flamm,et al.  Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer. , 1990, European urology.

[29]  R Sylvester,et al.  Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cance , 1992, The Journal of urology.

[30]  H. Huland,et al.  Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients. , 1983, European urology.

[31]  O. Dalesio,et al.  Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone. , 1984, The Journal of urology.

[32]  J. Witjes,et al.  Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. , 1998, The Journal of urology.

[33]  G. Lunglmayr,et al.  Absorption studies on intraluminal thio-tepa for topical cytostatic treatment of low-stage bladder tumors. , 1971, The Journal of urology.

[34]  Richie Jp Intravesical chemotherapy. Treatment selection, techniques, and results. , 1992 .

[35]  L. Ose L.D.L. AND TOTAL CHOLESTEROL IN CORD-BLOOD SCREENING FOR FAMILIAL HYPERCHOLESTEROLÆMIA , 1975, The Lancet.

[36]  W. Catalona,et al.  Urothelial Tumors of the Urinary Tract , 1992 .

[37]  F. Longo,et al.  Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors. , 1969, The Journal of urology.

[38]  M. Coleman,et al.  Hematologic effects of intravesicular thiotepa therapy for bladder carcinoma. , 1980, JAMA.

[39]  P. Rigatti,et al.  Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. , 1998, Urology.

[40]  H. C. Jones,et al.  Thiotepa in the treatment of tumours of the bladder. , 1961, Lancet.

[41]  F. Torti,et al.  Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. , 1991, Journal of the National Cancer Institute.

[42]  R. Badalament,et al.  Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  Cynthia N. Batts Adjuvant Intravesical Therapy for Superficial Bladder Cancer , 1992, The Annals of pharmacotherapy.

[44]  F. D. da Silva,et al.  4'-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer. , 1992, European urology.

[45]  R. Badalament,et al.  Treatment of superficial bladder cancer with intravesical chemotherapy. , 1997, Seminars in surgical oncology.

[46]  D. Byar,et al.  Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. , 1977, Urology.

[47]  B. Norlén,et al.  A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. , 1996, The Journal of urology.

[48]  R Sylvester,et al.  A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. , 1993, The Journal of urology.

[49]  C. Ed,et al.  Complications of intravesical chemotherapy. , 1992, The Urologic clinics of North America.

[50]  J. Witjes,et al.  A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. , 1995, The Journal of urology.

[51]  J. Flamm,et al.  Adjuvant intravesical mitoxantrone after transurethral resection of primary superficial transitional cell carcinoma of the bladder. A prospective randomised study. , 1995, European journal of cancer.

[52]  Huben Rp Intravesical chemotherapy versus immunotherapy for superficial bladder cancer. , 1996 .

[53]  R. Allman,et al.  Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line. , 1997, British Journal of Cancer.

[54]  W. Taylor,et al.  Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. , 1983, The Journal of urology.

[55]  R Sylvester,et al.  Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. E , 1995, The Journal of urology.

[56]  F. Micali,et al.  Electromotive delivery of mitomycin C into human bladder wall. , 1997, Cancer research.

[57]  M. Bibby,et al.  ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour , 1996, Cancer Chemotherapy and Pharmacology.

[58]  S. Krege,et al.  A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. , 1996, The Journal of urology.

[59]  R. Kinne,et al.  Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C. , 1996, The Journal of urology.

[60]  B. Norlén,et al.  5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. , 1999, The Journal of urology.